168 related articles for article (PubMed ID: 33396968)
41. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
Gazzard BG
Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
[TBL] [Abstract][Full Text] [Related]
42. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
Keller MJ; Wood L; Billingsley JM; Ray LL; Goymer J; Sinclair S; McGinn AP; Marzinke MA; Frank B; Srinivasan S; Liu C; Atrio JM; Espinoza L; Mugo N; Spiegel HML; Anderson PL; Fredricks DN; Hendrix CW; Marrazzo J; Bosinger SE; Herold BC
Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Wong A; Goldstein D; Mallolas J; DeJesus E; Johnson M; Molina JM; Pozniak A; Rodgers A; Teal V; Hepler D; Kumar S; Sklar P; Hanna GJ; Hwang C; Badshah C; Teppler H
J Acquir Immune Defic Syndr; 2019 Dec; 82(4):e47-e49. PubMed ID: 31425317
[TBL] [Abstract][Full Text] [Related]
44. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
45. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
47. Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Ramanathan R; Jiang Y; Read B; Golan-Paz S; Woodrow KA
Acta Biomater; 2016 May; 36():122-31. PubMed ID: 26947382
[TBL] [Abstract][Full Text] [Related]
48. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
49. A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
Schlesinger E; Johengen D; Luecke E; Rothrock G; McGowan I; van der Straten A; Desai T
Pharm Res; 2016 Jul; 33(7):1649-56. PubMed ID: 26975357
[TBL] [Abstract][Full Text] [Related]
50. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
51. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Orkin C; Squires KE; Molina JM; Sax PE; Wong WW; Sussmann O; Kaplan R; Lupinacci L; Rodgers A; Xu X; Lin G; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C; Martin EA;
Clin Infect Dis; 2019 Feb; 68(4):535-544. PubMed ID: 30184165
[TBL] [Abstract][Full Text] [Related]
52. The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
Dubrocq G; Rakhmanina N
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):773-779. PubMed ID: 29985071
[TBL] [Abstract][Full Text] [Related]
53. 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery.
Siyawamwaya M; du Toit LC; Kumar P; Choonara YE; Kondiah PPPD; Pillay V
Eur J Pharm Biopharm; 2019 May; 138():99-110. PubMed ID: 29655904
[TBL] [Abstract][Full Text] [Related]
54. Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.
Watkins ME; Wring S; Randolph R; Park S; Powell K; Lutz L; Nowakowski M; Ramabhadran R; Domanico PL
J Pharm Sci; 2017 Mar; 106(3):906-919. PubMed ID: 27986599
[TBL] [Abstract][Full Text] [Related]
55. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Margot NA; Isaacson E; McGowan I; Cheng A; Miller MD
J Acquir Immune Defic Syndr; 2003 May; 33(1):15-21. PubMed ID: 12792350
[TBL] [Abstract][Full Text] [Related]
56. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
[TBL] [Abstract][Full Text] [Related]
57. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity.
Murphy RA; Stafford RM; Petrasovits BA; Boone MA; Valentovic MA
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257038
[TBL] [Abstract][Full Text] [Related]
58. Multipurpose prevention technologies: products in development.
Friend DR; Clark JT; Kiser PF; Clark MR
Antiviral Res; 2013 Dec; 100 Suppl():S39-47. PubMed ID: 24188708
[TBL] [Abstract][Full Text] [Related]
59. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321
[TBL] [Abstract][Full Text] [Related]
60. Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Yee KL; DiBenedetto A; Fan L; Khalilieh S; Triantafyllou I; Vallee MH; Fackler P; Stoch SA; Iwamoto M
AAPS PharmSciTech; 2020 Feb; 21(3):91. PubMed ID: 32060665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
